Journal of Bioequivalence & Bioavailability

Mimovirus: a novel form of vaccine induced specifi c cytotoxic T lymphocyte responses in vivo

2^nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

06-08 June 2011, Las Vegas, USA

Yu-Zhang Wu

Scientific Tracks Abstracts: JBB

Abstract:

C D8+ cytotoxic T lymphocytes (CTLs) are recognized as important mediators of immunity against tumors and intracellular infections. How to evolke antigen- specifi c CTL response in vivo is still a problem in therapeutic vaccine development . Here, we reported that a completely novel CTL vaccine� mimovirus, a kind of virus- sized particulate antigen delivery system, effi ciently induced CTL response in vivo. It was produced by using a cationic peptide containing 18 lysines, a CTL-epitope peptide of HBsAg28-39 and a plasmid encoding mouse IL-12 through self-assembly and electrostatic interactions. It was demonstrated that mimovirus can effi ciently deliver the CTL epitope into the MHC class I processing pathway of professional antigen-presenting cells (APCs), thereby crosspriming an HBsAg28-39-specifi c CTL response in vivo. For its eff ectiveness, safety, fl exibility, easiness to be produced and its composition easily defi ned, mimovirus has the potential to be developed as an effi cient therapeutic vaccine against tumors and intracellular infections